HANGZHOU, China and SAN FRANCISCO , Jan. 23, 2024 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic diseases, today announced positive interim results from the first four cohorts of a Phase 1 clinical trial of oral ecnoglutide (XW004). Ecnoglutide is a long-acting, cAMP signaling biased, glucagon-like peptide-1 (GLP-1) analog that is being developed for the treatment of type 2 diabetes and obesity. XW004 is an oral tablet formulation of ecnoglutide.
Sciwind Biosciences has furthered its plans to challenge Novo Nordisk’s Ozempic for the Chinese type 2 diabetes market, linking its rival GLP-1 drug to reductions in blood glucose and body weight in a phase 3 clinical trial.
HANGZHOU, China and SAN FRANCISCO, July 11, 2023 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focusing on discovering and developing innovative therapies to treat metabolic disease, today announced the publication of discovery, preclinical characterization, and Phase 1 clinical trial results of its GLP-1 analog ecnoglutide (XW003) in Molecular Metabolism.
HANGZHOU, China and SAN FRANCISCO, Jan. 30, 2023 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic disease, announced today the initiation of patient dosing in Phase 3 clinical trials of ecnoglutide (XW003) in adult patients with type 2 diabetes in China. Ecnoglutide is a novel, long-acting glucagon-like peptide-1 (GLP-1) analog optimized for improved biological activity, cost-effective manufacturing, and once-weekly dosing. It was shown to be safe and well tolerated, as well as to result in robust HbA1c and weight reductions in Phase 2 clinical trials.
SAN FRANCISCO and HANGZHOU, China, Oct. 27, 2022 /PRNewswire/ -- Sciwind Biosciences, a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic disease, announced today positive results from an interim analysis of the on-going Phase 2b clinical trial of XW003 (ecnoglutide) in patients with obesity. XW003 is a novel, long-lasting glucagon-like peptide-1 (GLP-1) analog being developed for the treatment of type 2 diabetes and obesity.
Sciwind Biosciences has commenced subject dosing in a Phase I clinical trial of new oral drug, XW014, in development to treat obesity and type 2 diabetes.
HANGZHOU, China and SAN FRANCISCO, Oct. 9, 2022 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic disease, announced today the initiation of dosing in a Phase 1 clinical trial evaluating XW014, a novel oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist. XW014 is being developed for the treatment of obesity and type 2 diabetes.
Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat...
Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat...
HANGZHOU, China and SAN FRANCISCO, June 8, 2022 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focusing on discovering and developing innovative therapies to treat metabolic disease, today announced that two abstracts have been accepted for poster presentations at The International Liver CongressTM 2022, the Annual Meeting of the European Association for the Studies of the Liver (EASL) taking place June 22-26 in London, United Kingdom. During the meeting, data from a combination study of Sciwind's long-lasting GLP-1 peptide analog XW003 and GIP peptide analog XW017 in an obese mouse model and preclinical pharmacology data for the oral small molecule GLP-1 receptor agonist XW014 will be featured in two poster presentations.